Cognitive Dysfunction and Dementia in Primary Sjögren’s Syndrome

Blanc, F.; Longato, Nadine; Jung, Barbara; Kleitz, Catherine; Bitonto, Laure Di; Crétin, Benjamin; Collongues, Nicolas; Sordet, Christelle; Fleury, Marie; Gottenberg, Jacques-Éric; Anne, Olivier; Lipsker, Dan; Martin, Thierry; Sibilia, Jean; Sèze, Jérôme De

doi:10.1155/2013/501327

Cited by 21 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cognitive impairment was also correlated with the presence of white matter lesions. 14 In our study, no correlation was established between delayed recall memory impairment and MRI findings, although not all patients )%62.5( had MRI evaluations. Unlike the studies by Mataro and F. Blanc, in our study, the mean age was lower and diseases such as migraine, seizure or neuropsychiatric involvement did not accompany patients with PSS.…”

contrasting

confidence: 60%

“…11 Increased white matter abnormality was defined in PSS patients however in some studies, it was not different from the normal population. [11][12][13] Similarly, some studies found a relationship between cognitive impairment and white matter lesions )WMLs(, 14 whereas this was not supported in other studies. 5,6 Previous studies did not mention a specific test for detecting cognitive dysfunction in PSS; in addition, some cognitive tests are expensive and time-consuming.…”

mentioning

confidence: 91%

“…23 However, it should be considered that these findings may be due to age and cerebrovascular risk factors, since PSS is prevalent in the age group of 40-50 years. 24 With respect to the relationship between the duration of the disease and WMLs, a study by F. Blanc et al 14 established a correlation between WMLs and cognitive impairment, and the authors reported a span of 10 years between the onset of PSS symptoms and cognitive complaints.In our study, there was no difference in cognitive functions, except delayed recall, which can be ascribed to the short duration of the disease.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Montreal cognitive assessment in primary sjogren’s syndrome

Kurtuluş

Çay

Parlak

et al. 2019

NSJ

View full text Add to dashboard Cite

Objectives: To use the Montreal Cognitive Assessment)MoCA(test to assess the subclinical cognitive impairment in patients with Primary Sjögren's Syndrome)PSS(and assess the correlation of MoCA results with magnetic resonance imaging)MRI(findings in these patients. Methods: The MoCA test was prospectively administered to 32 consecutive patients)31 females, 1 male(diagnosed with PSS and 30 healthy controls)29 females, 1 male(at Antalya Education and Research Hospital between June 2014 and October 2015. Twenty PSS patients underwent a brain MRI)T1, T2, and T2-FLAIR-weighted sequences(. Results: The mean age was 45.84)range 24-63(in the PSS group, and the mean duration of disease was 3.5 years)4 months-18 years(. There were 22 patients)68.80%(with 5-8 years of education and 10 patients)31.30%(with >8 years of education. The mean age was 42.8)28-64(in the control group. There were 20 controls)66.70%(with 5-8 years of education and 10 controls)33.3%(with >8 years of education. The delayed recall rate of the patient group with 5-8 years of education was significantly lower than that of the control group, and the recall rate with multiple choice cues for the same patient group was significantly higher than that of the control group)p<0.05(. There was no correlation between the number of lesions and total MoCA score or subgroups. Conclusion: We suggest that the MoCA test is a single-page, easy-to-administer test, can be used to assess cognition in patients with PSS especially in large groups.

show abstract

contrasting

confidence: 60%

mentioning

confidence: 91%

mentioning

confidence: 99%

See 1 more Smart Citation

Montreal cognitive assessment in primary sjogren’s syndrome

Kurtuluş

Çay

Parlak

et al. 2019

NSJ

View full text Add to dashboard Cite

show abstract

“…Other studies have found similar results not encountering differences in the total score of the tests but abnormal subdomain results in frontal-subcortical dysfunction areas. 5,[15][16][17] Even though the automatized test ANAM has not been previously assessed in SS, it has already been proven to be a useful screening tool for cognitive impairment in SLE patients. In conclusion, we did not find a difference in the prevalence of cognitive impairment, in pSS subjects versus controls by the MoCA.…”

Section: Discussionmentioning

confidence: 99%

Cognitive dysfunction in Sjögren’s syndrome using the Montreal Cognitive Assessment Questionnaire and the Automated Neuropsychological Assessment Metrics: A cross‐sectional study

et al. 2020

View full text Add to dashboard Cite

Aim: To describe the prevalence of cognitive impairment and the most affected cognitive domains, employing the Montreal Cognitive Assessment (MoCA) and the Automated Neuropsychological Assessment Metrics (ANAM) of a Latin American primary Sjögren's syndrome (pSS) cohort, and compare these patients to secondary Sjögren's syndrome (sSS) subjects and controls. Methods: This was a comparative cross-sectional study of patients with a diagnosis of pSS who fulfilled the American-European Consensus Group 2002 criteria and/ or American College of Rheumatology/European League Against Rheumatism 2016 criteria; clinical information was evaluated prior to cognitive evaluation, which consisted of a single session in which the MoCA and ANAM were applied. Results: A total of 122 subjects were included in the analysis (51 pSS, 20 sSS and 51 controls); mean age of pSS was 56 years (SD 10.4), of which 47 (92.15%) were women. Moderate-severe cognitive impairment by MoCA was 17% in pSS, 5% in sSS, and 15% in controls, and by ANAM were 29% in pSS and 10% in sSS (P > .05). Visuospatial/ executive subdomain in the MoCA was different between the pSS and the control group (P = .005). We encountered a statistically significant difference between pSS patients and control scores from the program in 6 of the 7 domains tested by the ANAM. Conclusion: No difference was found in the prevalence of cognitive impairment between pSS subjects and controls by MoCA. Several subdomain scores differed between groups in both scales. Evaluation of cognitive disorders in patients with SS, even in early stages of the disease, seems advisable but the best strategy is yet to be elucidated. How to cite this article: Riega-Torres JCL, Treviño-Castro MA, Hernandez-Galarza IDJ, et al. Cognitive dysfunction in Sjögren's syndrome using the Montreal Cognitive Assessment Questionnaire and the Automated Neuropsychological

show abstract

“…For patients reporting memory deficit, dementia or cognitive dysfunction, these white matter lesions are always present [ 32 , 43 – 48 ]. In one case of dementia, an Electroencephalogram (EEG) agreed with the SPECT findings above, identifying in the parietal lobes short runs of theta activities; symptoms improved with treatment of corticosteroids [ 49 ].…”

Section: Brain Lesionsmentioning

confidence: 99%

Beyond the Glands: An in-Depth Perspective of Neuropathy in Sjögren’s Syndrome

Voigt

Sukumaran

Nguyen³

2014

Rheumatology (Sunnyvale)

View full text Add to dashboard Cite

Primary Sjögren’s Syndrome (pSjS) is an autoimmune disease characterized by sicca (xerophthalmia or xerostomia) symptoms, anti-SS-A (Ro) or anti-SS-B (La) autoantibodies, and lymphocytic infiltrates in the exocrine glands. Disease incidence is estimated to be 0.1–3% of the general population with 0.4–3.1 million individuals in the US with women being nine times more likely to be afflicted with SjS than men. The frequency continues to rise accompanied with the multi-factorial etiology making it a challenging disease to manage and treat. Treatment of this disease remains problematic due to the lack of therapeutic treatments relying on replacement therapies such as artificial saliva and eye lubricants or immunosuppressive agents. To further complicate the management of the disease, there are number of multi-systemic manifestations specifically peripheral neuropathy associated with later stage of disease onset. Increasingly, there is mounting evidence that suggests the involvement of central nervous system. It remains to be determined the underlying cause and effect of the dysregulated immune response and the neuropathy associated with SjS. In this review, we provided an in-depth look at key neurological dysfunctions documented to occur in pSjS. Specifically, we discussed the prevalence, symptomology, and current treatments.

show abstract

Cognitive Dysfunction and Dementia in Primary Sjögren’s Syndrome

Cited by 21 publications

References 25 publications

Montreal cognitive assessment in primary sjogren’s syndrome

Montreal cognitive assessment in primary sjogren’s syndrome

Cognitive dysfunction in Sjögren’s syndrome using the Montreal Cognitive Assessment Questionnaire and the Automated Neuropsychological Assessment Metrics: A cross‐sectional study

Beyond the Glands: An in-Depth Perspective of Neuropathy in Sjögren’s Syndrome

Contact Info

Product

Resources

About